TORONTO, Feb. 19 /PRNewswire/ - Defyrus Inc. today announced the signing an exclusive, worldwide license to a patent portfolio created by the United Kingdom's Defence Science and Technology Laboratory (Dstl) and licensed by Ploughshare Innovation Ltd, Dstl's commercialization company. These patents form the intellectual property foundation of the Company's vaccine product development programs. Defyrus and Ploughshare Innovation Ltd plan to expand their commercial interaction in 2009 to include preclinical safety and efficacy studies as part of the Company's vaccine development program. The commercial terms of the license were not disclosed.
The licensed technology of 27 issued & pending international patents, describes the production of multi-valent vaccines for the treatment of alpha-viral infections resulting from bioterrorism or endemic disease. These highly infectious, mosquito-borne encephalitis viruses pose a serious risk to people and livestock for which no vaccine or therapy exists.
"Dstl has pioneered the investigation of effective medical countermeasures (e.g. vaccines and drugs) for the treatment of a number of important biological diseases that are potential biological warfare threats. Their unique approach to vaccine development and compelling animal efficacy data for viral encephalitis made this license attractive" commented Dr. Jeffrey D. Turner, President & CEO of Defyrus, "We see tremendous synergy in levering investor capital with successful Government R&D programs to drive cost-effective, rapid drug development forward. Improving our capability to respond to viral threats from endemic disease or biological warfare is our mission and represents a significant contribution to protecting the international community from dangerous pathogens".
"Defyrus' business model has the hallmark of a true public-private collaboration. In licensing Dstl's technology to Defyrus, whose management team have a proven track record in vaccine development, Ploughshare expects that Dstl's pioneering work can be rapidly translated into vaccines that are available for both the public health markets in the developing world, as well as the North American and European defence markets" stated Andy Tulloch, Chief Executive Officer Ploughshare Innovations. "We look forward to expanding our interactions with Defyrus in the years to come" added Dr. David Harris, Head of Technology Transfer at Dstl.
About Defyrus
Defyrus is a private, life sciences biodefence company that collaborates with domestic and international military R&D partners to develop a range of therapeutics as medical countermeasures for civilians and military personnel. www.defyrus.com
About Ploughshare Innovations & Dstl
Ploughshare is wholly owned by the United Kingdom's Secretary of State for Defence and facilitates the commercialization of defence technologies arising from Dstl. Dstl is an agency of the UK's Ministry of Defence (MoD), existing to supply the very best, impartial, scientific and technical research and advice to the MoD and other Government Departments. Dstl houses one of the largest groups of scientists and engineers (3,500-strong work force) in public service in the UK and supports procurement decisions, defence policy-making and operations. www.ploughshareinnovations.com & www.dstl.gov.uk
'/>"/>
| SOURCE Defyrus Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |